Literature DB >> 17563565

Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients.

Jan Václavík1, David Stejskal, Borek Lacnák, Marie Lazárová, Libor Jedelský, Lenka Kadalová, Marie Janosová, Zdenek Frysák, Petr Vlcek.   

Abstract

OBJECTIVES: Detection of free plasma metanephrines seems to be the most exact method for biochemical diagnosis of pheochromocytoma, but their diagnostic efficacy in the common low-risk clinical settings is debated.
METHODS: A cross-sectional multicentre study including 1260 subjects assessed the diagnostic efficacy of free plasma metanephrine and normetanephrine in low-risk patients screened for resistant or markedly accelerated hypertension, paroxysmal hypertension, 'flushes' and, in a small proportion, for adrenal incidentaloma or genetic predisposition to pheochromocytoma.
RESULTS: Pheochromocytoma was identified and verified by histology in 25 subjects (2%), with the diagnosis not confirmed by long-term follow-up or use of imaging techniques in the remaining 1235 individuals. The combined assay of free plasma metanephrines was a highly sensitive (100%) and specific (96.7%) measure, yielding a negative predictive value of 100%.
CONCLUSION: The satisfactory diagnostic efficacy of free plasma metanephrines allows their use as a single screening test in cases of suspected pheochromocytoma in the population with a low pretest probability.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17563565     DOI: 10.1097/HJH.0b013e32813aeb5a

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  18 in total

Review 1.  Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review.

Authors:  Roland Därr; Matthias Kuhn; Christoph Bode; Stefan R Bornstein; Karel Pacak; Jacques W M Lenders; Graeme Eisenhofer
Journal:  Endocrine       Date:  2017-04-12       Impact factor: 3.633

Review 2.  Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification.

Authors:  Graeme Eisenhofer; Arthur S Tischler; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

3.  Pheochromocytoma and paraganglioma.

Authors:  Vitaly Kantorovich; Karel Pacak
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

Review 4.  The importance of standardisation of measurement and reference intervals for detection of phaeochromocytoma and paraganglioma (PPGL).

Authors:  Tomás P Griffin; Delia Bogdanet; Patrick Navin; Grace Callagy; Paula M O'Shea; Marcia Bell
Journal:  Ir J Med Sci       Date:  2018-02-19       Impact factor: 1.568

5.  Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma.

Authors:  Graeme Eisenhofer; Peter Lattke; Maria Herberg; Gabriele Siegert; Nan Qin; Roland Därr; Jana Hoyer; Arno Villringer; Aleksander Prejbisz; Andrzej Januszewicz; Alan Remaley; Victoria Martucci; Karel Pacak; H Alec Ross; Fred C G J Sweep; Jacques W M Lenders
Journal:  Ann Clin Biochem       Date:  2012-10-12       Impact factor: 2.057

Review 6.  A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors.

Authors:  Ioannis Ilias; Karel Pacak
Journal:  Nucl Med Biol       Date:  2008-08       Impact factor: 2.408

Review 7.  Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome.

Authors:  Karel Pacak; Graeme Eisenhofer; Ioannis Ilias
Journal:  Hormones (Athens)       Date:  2009 Apr-Jun       Impact factor: 2.885

Review 8.  Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism.

Authors:  William F Young
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

Review 9.  Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas.

Authors:  G Eisenhofer; G Siegert; J Kotzerke; S R Bornstein; K Pacak
Journal:  Horm Metab Res       Date:  2008-05       Impact factor: 2.936

10.  Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma.

Authors:  Jacques W M Lenders; Karel Pacak; Thanh-Truc Huynh; Yehonatan Sharabi; Massimo Mannelli; Gennady Bratslavsky; David S Goldstein; Stefan R Bornstein; Graeme Eisenhofer
Journal:  J Clin Endocrinol Metab       Date:  2009-11-06       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.